Aktienanalyse wird geladen …
VEEV · NYSE · Software · USA
280,68 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 3,2 Mrd. | 908,91 Mio. | 5,44 $ | 167 Mio. | 1,7 Mio · 1 % | — | 75,5 % | 28,4 % | 8,47 $ | 2,83 $ | — |
| 2024 | 2,75 Mrd. | 714,14 Mio. | 4,32 $ | 165,23 Mio. | 1,6 Mio · 0,9 % | — | 74,5 % | 26 % | 6,60 $ | 2,65 $ | — |
| 2023 | 2,36 Mrd. | 525,71 Mio. | 3,22 $ | 163,49 Mio. | 1,4 Mio · 0,9 % | 0,4 Mio · 0,2 % | 71,4 % | 22,2 % | 5,57 $ | 2,41 $ | — |
| 2022 | 2,16 Mrd. | 487,71 Mio. | 3,00 $ | 162,44 Mio. | 1,3 Mio · 0,8 % | 1,1 Mio · 0,7 % | 71,7 % | 22,6 % | 4,80 $ | 2,17 $ | — |
| 2021 | 1,85 Mrd. | 427,39 Mio. | 2,63 $ | 162,28 Mio. | 0,8 Mio · 0,5 % | — | 72,8 % | 23,1 % | 4,71 $ | 1,45 $ | — |
| 2020 | 1,47 Mrd. | 380 Mio. | 2,36 $ | 160,73 Mio. | 0,7 Mio · 0,4 % | — | 72,1 % | 25,9 % | 3,43 $ | 1,15 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge |
|---|---|---|---|---|---|---|
| Q3 2026 | 927,96 Mio. | 273,43 Mio. | 1,66 $ | 165,06 Mio. | 75 % | 29,5 % |
| Q2 2026 | 882,95 Mio. | 260,94 Mio. | 1,57 $ | 165,99 Mio. | 75 % | 29,6 % |
| Q1 2026 | 835,95 Mio. | 244,2 Mio. | 1,45 $ | 168,26 Mio. | 74,5 % | 29,2 % |
| Q4 2025 | 811,24 Mio. | 236,2 Mio. | 1,40 $ | 168,94 Mio. | 75,4 % | 29,1 % |
| Q3 2025 | 789,08 Mio. | 200,31 Mio. | 1,19 $ | 167,69 Mio. | 75,3 % | 25,4 % |
| Q2 2025 | 759,04 Mio. | 228,19 Mio. | 1,37 $ | 166,23 Mio. | 77,1 % | 30,1 % |
| Q1 2025 | 720,89 Mio. | 195,63 Mio. | 1,17 $ | — | 74,9 % | 27,1 % |
| Q4 2024 | 699,21 Mio. | 185,81 Mio. | 1,13 $ | 164,98 Mio. | 75,1 % | 26,6 % |
Veeva Systems (VEEV) Outperforms Broader Market: What You Need to Know
Veeva Unveils AI Study Builder Agent to Speed Clinical Trial Setup
Veeva (VEEV) Down 2.6% Since Last Earnings Report: Can It Rebound?
How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients
Veeva Systems (VEEV) Could Be 29% Undervalued Following Its New AI Study Design Launch
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Quality Management System Software Market Forecasts Growth from $11.73B (2026) to $20.43B by 2031, Profiling Veeva Systems, Siemens, PTC, SAP, Oracle & 15 Others
Veeva Systems Inc. is a cloud software company that provides industry-specific solutions for the global life sciences sector. Veeva Systems Inc. offers applications, data, and consulting services designed to support pharmaceutical, biotechnology, and medical device companies across research and development, quality, and commercial operations. Its product portfolio includes platforms for clinical, regulatory, quality, and field activities, along with customer relationship management, content management, analytics, and data services tailored to life sciences workflows. The company also delivers cloud-based tools that help organizations manage complex processes from drug development through commercialization. Veeva Systems Inc. plays a central role in the life sciences technology market by combining software and data in a specialized industry cloud built for highly regulated environments. Founded in 2007 and headquartered in Pleasanton, California, the company focuses on serving customers that need compliant, scalable digital systems for critical business functions.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest VEEV und jede andere Aktie unbegrenzt.